比亞迪(01211.HK)再向北歐Nobina交付76架純電動大巴
比亞迪(01211.HK)宣布,於8月10日向北歐最大公共交通運營商Nobina集團交付76架純電動大巴,車隊涵蓋旗下純電動巴士家族4款車型,將於本月於芬蘭首都赫爾辛基投入營運。
是次交付純電動大巴車型涵蓋12米、13米大巴,全新15米城際大巴和18米鉸鏈式大巴,當中全新18米純電動鉸鏈式大巴搭載頂部充電功能,載客量高達112人;首次投入大規模商業化運營的15米城際純電動巴士配有50個座椅,載客量90人以上。
計及上月交付予圖爾庫市的43架大巴,比亞迪交付予Nobina的電動巴士車隊增至119架。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.